NICE approves Bayer’s Eylea for NHS use

September 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Eylea, NICE

Bayer has announced that its Eylea (aflibercept) drug has received a final recommendation from NICE for the treatment of visual …

GW Pharma releases positive data on cannabidiol-based Phase III trial

September 28, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis

GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …

Malaysian pharmaceutical market set to grow to $3.6 billion by 2020

September 28, 2016
Research and Development

The report, by GlobalData, states that the primary reasons behind this growth are linked to medical tourism, a lack of …

AbbVie and Eisai celebrate approval of new Humira indication

September 28, 2016
Research and Development, Sales and Marketing AbbVie, Eisai, Humira

AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …

Zuckerberg appoints AstraZeneca’s Cornelia Bargmann

September 28, 2016
Research and Development AstraZeneca, Facebook, Mark Zuckerberg, Priscilla Chan

Zuckerberg and Chan have committed $3 billion of their own money to setting up the health initiative that has an …

80% of Chinese clinical trials’ data fabricated

September 28, 2016
Manufacturing and Production, Research and Development China, Fabrication, corruption, report

The government review of clinical trial practise involved 1,622 programs of new pharmaceutical drugs waiting upon government approval to begin …

Provisional NICE recommendation for Gilead’s Hepatitis C treatment

September 28, 2016
Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C

NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …

Merck elects Isabel De Paoli as CSO

September 27, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

Amgen’s Kyprolis disappoints in Phase III trial

September 27, 2016
Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III

Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …

Kite Pharma flying high after promising Car-T trial

September 27, 2016
Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma

Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …

Price-hiked EpiPen profits 66% higher than Mylan CEO claimed

September 27, 2016
Business Services, Manufacturing and Production, Sales and Marketing Heather Bresch, Mylan, epipen

In the latest development in the Mylan EpiPen scandal, it has been discovered that CEO Heather Bresch lied to US …

Sanofi secures $43 million government funding for zika vaccine development

September 27, 2016
Manufacturing and Production, Research and Development BARDA, Sanofi, Zika

The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the …

Johnson & Johnson’s Stelara receives FDA approval

September 27, 2016
Manufacturing and Production, Research and Development Janssen Biotech, Johnson & Johnson, Stelara

The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated …

Biogen closes in on bringing muscular atrophy preventing drug to market

September 26, 2016
Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen

Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …

CPHI Worldwide: PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules

September 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CPhI

Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) …

Pfizer decides not to break up business

September 26, 2016
Sales and Marketing Ian Read, Pfizer, United States, america

In the intervening four years, Pfizer has conducted “extensive evaluation” into the possibility, with the company reorganising into two distinct …

Australian pharmaceutical market to grow to be worth $25 billion by 2020

September 26, 2016
Business Services, Sales and Marketing Australia, Australian Government

The Australian market, in 2016, is currently worth over $22.85 billion and is predicted to reach $25.2 billion by 2020, …

Sanofi and Regeneron’s atopic dermatitis drug secures FDA priority review

September 26, 2016
Research and Development, Sales and Marketing

Regeneron and Sanofi have announced that the US Food and Drug Administration has granted priority review for the pair’s atopic …

Merck elects Isabel De Paoli as CSO

September 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

Woodley Equipment Company to Attend ICSE Exhibition, Barcelona

September 26, 2016
Clinical Trials Supplier, medical and laboratory equipment provider

Woodley Equipment is attending ICSE Exhibition taking place on 4th to 6th October 2016 at Fira de Barcelona Gran Via, Barcelona, Spain. 

The Gateway to Local Adoption Series

Latest content